Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05112991
Study type Interventional
Source 3D Medicines
Contact bin She
Phone 15973143911
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date January 2022
Completion date October 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04574284 - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer Phase 2
Not yet recruiting NCT05077215 - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer Phase 3
Completed NCT01289041 - BKM120 as Second-line Therapy for Advanced Endometrial Cancer Phase 2
Not yet recruiting NCT05106127 - Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem Phase 2